ArticleMolecular cancer therapeutics2019

EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.

Suryavathi Viswanadhapalli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.